Pediatric Drug Development in China Receives New Guidance and SPARK Program

Pediatric drug development in China received new guidance and a support program on May 29, 2025. On that date, the Center for Drug Evaluation (CDE) officially implemented two key policies—the Technical Guidance for the Safety Information Assessment and Reporting of Pediatric Drug Clinical Trials (Trial) (No. 2025/21), and the Notification on the Issuance of the Pilot Program for the Support of Anti-tumor Drugs R&D for Kids (SPARK Program). These developments establish a dual-track regulatory approach combining technical safety oversight with targeted incentives. International pharmaceutical companies conducting or planning pediatric drug trials in China should assess their compliance strategies in light of the new safety reporting requirements and potential opportunities under the SPARK Program.

Background and Positioning Differences of the Two Policies

The "Technical Guidance for the Safety Information Assessment and Reporting of Pediatric Drug Clinical Trials (Trial)" (hereinafter referred to as the "Guidance") was released and officially implemented on May 23, 2025. It is the first technical document in China specifically targeting the management of safety information in pediatric drug clinical trials, filling the professional gap in China's pediatric pharmacovigilance field. The Guidance systematically regulates the safety risk assessment and reporting mechanism for pediatric drug clinical trials involving children under 18 years of age (including premature neonates), constructing a safety protection net for pediatric drug use from multiple dimensions such as ethical considerations, risk monitoring, and reporting procedures.

The Guidance (Notification No. 2025/21), issued on May 23, 2025, applies to clinical trials involving traditional Chinese medicine, chemical drugs, and biological products, while specifically excluding preventive biological products. Clinical trial design and implementation under this guideline should also refer to Good Clinical Practice (GCP), ICH guidelines, and other relevant domestic guidelines to ensure regulatory consistency.

The "Pilot Program for the Support Anti-tumor Drugs R&D for Kids (SPARK Program)" was also released and officially implemented on May 29, 2025. This is a special incentive policy launched by the CDE for the specific field of pediatric tumors. The program aims to address the challenges in the development of pediatric antitumor drugs through "early involvement, tailored strategies for each enterprise, comprehensive guidance, and integrated research and review," accelerating the fulfillment of the "great unmet clinical need" in this area. Although pediatric tumors are rare or infrequent diseases, they pose significant harm to society and families, and the global development of antitumor drugs for pediatric patients has long been insufficient.

There are clear differences in the positioning of the two policies: The Guidance is a technical regulation applicable to all pediatric drugs and has a universal nature; whereas the SPARK Program is a special support policy for pediatric antitumor drugs and has field specificity. This difference precisely reflects the regulatory authorities' approach of classified management and targeted policy-making—establishing unified safety standards while providing special support for specific fields.

From a policy hierarchy perspective, the Guidance is a technical document that provides specific operational guidance for enterprises; whereas the SPARK Program is an innovative practice of the review and approval system, reducing the uncertainty of enterprise research and development by optimizing regulatory processes. The two complement each other and together form the policy cornerstone of China's pediatric drug development.

Core Content and Complementary Relationship of the Two Policies

A detailed analysis of the specific content of the two policies reveals a high degree of complementarity and synergistic effects, jointly constructing a complete policy chain of "front-end incentives + back-end regulation."

• Enhanced Informed Consent Mechanism: It explicitly requires that children aged 8 years and above, in addition to obtaining consent from their guardians, must also sign an informed consent form themselves. This is stricter than the standard in the 2016 "Technical Guidance for Pediatric Drug Clinical Trials," which stated that "children aged 10 years and above should generally participate in informed consent."
• Risk Classification and Management: It systematically proposes three major categories of risks unique to pediatric drug clinical trials—information deficiency risk, development-related risk, and formulation compatibility risk—and requires sponsors to develop a clinical risk management plan in the early stages of research and development.
• Safety Information Reporting Requirements: It puts forward pediatric-specific requirements for individual case safety reports (ICSRs) and development safety update reports (DSURs), such as analyzing data by age subgroups and recording developmental indicators in detail.
• Professional Team and Communication Mechanism: It requires the presence of personnel with pediatric professional backgrounds to handle safety reports and encourages the use of child-friendly information carriers (such as comics and videos) for safety education.

The SPARK Program, on the other hand, designs four support mechanisms around the pain points of pediatric antitumor drug development:

• Early Involvement Mechanism: Applicants can engage in early communication with the drug review center by submitting the Implementation Framework for the SPARK Program to obtain technical guidance throughout the process. This mechanism is designed to implement the NMPA’s strategic directive of “early intervention, one policy for one enterprise, whole-process guidance, and R&D-evaluation linkage.”
• Personalized Support: The CDE forms a tumor review team to provide tailored guidance and feedback for each enterprise.
• Full-Cycle Communication: Maintaining close communication throughout the research and development process to form an efficient collaborative mechanism of "integrated research and review."
• Flexible Access: There is no limit on the number of applications, with a three-year application window, supporting the same product to apply for multiple pediatric tumor indications.

The SPARK Program also aims to enhance communication efficiency by encouraging continuous interaction between applicants and the CDE. This structured dialogue not only facilitates issue resolution but also expedites pediatric oncology drug development and accelerates their entry into the market, thereby better meeting urgent patient needs.

The complementarity of the two policies is reflected in multiple dimensions:

• Research and Development Stage Coverage: The SPARK Program focuses on strategic guidance and path optimization in the early stages of research and development, while the Guidance focuses on safety management during the execution of clinical trials.
• Regulatory Logic Synergy: The SPARK Program reduces research and development barriers through resource allocation, while the Guidance ensures research quality through refined standards, forming a balanced approach of "liberalization and regulation."
• Data Requirement Connection: The SPARK Program encourages the use of advanced research and development tools such as extrapolation strategies and modeling simulations, while the Guidance sets safety assessment standards for the data generated by these methods.
• Professional Capacity Building: Both policies emphasize the importance of pediatric professional teams. The SPARK Program focuses on oncology expertise, while the Guidance focuses on pharmacovigilance capabilities, jointly promoting the construction of pediatric talent systems within enterprises.

It is particularly worth noting that the two policies are linked with the National Medical Products Administration's reform of reducing the review period for innovative drug clinical trials from 60 days to 30 days. Varieties selected for the SPARK Program can prioritize enjoying this policy benefit, while the regulatory requirements of the Guidance play a risk-balancing role to avoid potential safety hazards that may arise from accelerated review.

Strategic Significance and Industry Impact of Policy Synergy

Strategic Significance

The joint introduction of the two policies will have a profound impact on China's pediatric drug research and development ecosystem and holds multiple strategic significances.

• Filling the Institutional Gap in Pediatric Antitumor Drug Development: The field of pediatric tumor treatment has long faced a "treatment desert" dilemma. Among the children diagnosed with tumors globally each year, leukemia accounts for about 30%, brain and spinal cord tumors for about 25%, and neuroblastoma, nephroblastoma, and lymphoma each account for about 6%. However, the availability of targeted drugs is severely insufficient. China's pediatric drugs only account for 6% of the total number of drugs, and 90% need to be used off-label. The combined efforts of the two policies provide institutional guarantees for solving this problem by incentivizing enterprises to invest in this high-risk area through the SPARK Program and regulating the research and development process through the Guidance.
• Building a Full Life Cycle Regulatory System for Pediatric Drugs: From the perspective of drug development patterns, pediatric drugs require a special regulatory framework. On the one hand, children are different from adults, with different organ structures and physiological functions, and there are also significant differences among different age groups within the pediatric population. On the other hand, pediatric clinical trials face multiple challenges such as ethics, recruitment, and dose exploration. The two policies, from the dimensions of "acceleration" and "safety," respectively, build a regulatory system covering the full life cycle of pediatric drugs, bringing China's pediatric drug regulation in line with international advanced levels.
• Optimizing the Innovation Ecosystem of the Pharmaceutical Industry: For a long time, the development of pediatric drugs, especially pediatric antitumor drugs, has faced high research and development difficulties, large investments, limited market size, and insufficient enterprise enthusiasm. The SPARK Program reduces regulatory uncertainty, and the Guidance clarifies technical standards, jointly reducing the institutional costs for enterprises.
• Enhancing China's Voice in Global Pediatric Drug Development: Both policies reflect the absorption and innovation of international advanced experiences. For example, the Guidance refers to the age stratification recommendations in international guidelines such as ICH E11, and the SPARK Program draws on the acceleration mechanisms in the FDA's orphan drug policy. At the same time, the policies emphasize the importance of Chinese data. The Guidance requires detailed recording of China-specific pediatric data, and the SPARK Program encourages the development of formulations suitable for Chinese children. This model of "international experience + local innovation" will enhance China's ability to set rules in global pediatric drug development.

Industry Impact

The specific impact on the pharmaceutical industry mainly includes:

• Research and Development Model Transformation: Enterprises need to shift from "adult drug pediatricization" to "pediatric-specific development," such as focusing on formulation compatibility and developmental impact.
• Resource Reallocation: There is a need to increase the reserve of pediatric professionals, such as medical directors and pharmacovigilance experts with pediatric backgrounds.
• Data Standard Upgrade: Establishing an information system capable of capturing pediatric-specific data (such as gestational age, developmental stage).
• Reconstruction of Collaborative Networks: Establishing close cooperation with CROs and pediatric specialty hospitals with pediatric trial experience.

Corporate Response Strategies and Implementation Paths

Facing the opportunities and challenges brought by the two policies, pharmaceutical companies need to develop systematic response strategies, paying particular attention to the cross-requirements of the two policies—pediatric antitumor drug development participating in the SPARK Program must also comply with the safety management standards of the Guidance.

• Pipeline Prioritization Reassessment: Companies should reassess their research and development pipelines, prioritizing varieties with pediatric application prospects, especially antitumor indications. For projects that meet the SPARK Program criteria, they should actively apply within the three-year window period.
• Professional Team Building: In accordance with the requirements of the Guidance, form a cross-functional team with a pediatric background, including professionals in medicine, pharmacovigilance, clinical operations, etc. For small and medium-sized enterprises, they can consider establishing a talent-sharing mechanism with pediatric medical institutions.
• Process System Upgrade: Modify case report forms (CRFs) and safety databases to add pediatric-specific data fields; establish a risk communication mechanism that meets the requirements of the Guidance, such as developing child-friendly informed consent materials.
• Third-Party Collaboration Network: Choose partners with pediatric trial experience, especially CROs and research centers with successful cases in pediatric drug clinical trial institutions certified by the National Medical Products Administration.
• Regulatory Communication Mechanism: Fully utilize the Class I communication and exchange meetings provided by the SPARK Program and apply to the CDE for communication and exchange meetings at key research and development nodes.

Further Information

To read the official release of the Technical Guidance for the Safety Information Assessment and Reporting of Pediatric Drug Clinical Trials (Trial) published by the Center for Drug Evaluation on May 29, 2025, please visit the CDE announcement page. For details about the Pilot Program for Encouraging the Development of Pediatric Antitumor Drugs (SPARK Program), refer to the related notice from the CDE.

If you are a pharmaceutical manufacturer with questions about how China’s new pediatric drug policies affect your clinical trial planning or product development, please contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry

📚 Request our whitepapers

📣 Sign up for our newsletter